Registration statement for securities issued by foreign private issuers in certain business combination transactions

Condensed Consolidated Statement of Profit and Loss and Other Comprehensive Loss

v3.22.1
Condensed Consolidated Statement of Profit and Loss and Other Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Jun. 03, 2021
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Condensed Consolidated Statement of Profit and Loss and Other Comprehensive Loss            
Revenue   $ 266,446 $ 71,293 $ 322,921 $ 79,272 $ 16,034
Clinical care delivery expense   (23,927) (11,823) (289,672) (67,254) (19,810)
Claims expense   (247,552) (23,917)      
Platform & application expenses   (16,703) (6,434) (42,829) (38,137) (23,569)
Research & development expenses   (10,057) (10,390) (47,534) (54,711) (51,205)
Sales, general & administrative expenses   (58,310) (31,479) (196,673) (94,681) (84,270)
Recapitalization transaction expense $ (148,700)     (148,722)    
Operating loss   (90,103) (12,750) (402,509) (175,511) (162,820)
Finance costs   (6,628) (992) (14,291) (4,530) (1,116)
Finance income   255 14 326 610 1,015
Change in fair value of warrant liabilities   5,575   27,811    
Exchange loss   (447) (573) 868 (2,836) 17,075
Net finance expense   (1,245) (1,551) 14,714 (6,756) 16,974
Gain on sale of subsidiary     3,917 3,917    
Gain on remeasurement of equity interest       10,495    
Share of loss of equity-accounted investees     (455) (2,602) (1,124)  
Loss before taxation   (91,348) (10,839) (375,985) (183,391) (145,846)
Tax provision   (9) (8) 1,474 (4,639) 5,559
Loss for the period   (91,357) (10,847) (374,511) (188,030) (140,287)
Other comprehensive loss Items that may be reclassified subsequently to profit or loss:            
Currency translation differences   (3,753) (1,754) (1,702) 3,579 (9,693)
Other comprehensive loss for the period, net of income tax   (3,753) (1,754) (1,702) 3,579 (9,693)
Total comprehensive loss for the year   (95,110) (12,601) (376,213) (184,451) (149,980)
Loss attributable to:            
Equity holders of the parent   (91,357) (10,466) (368,482) (186,799) (140,287)
Non-controlling interest     (381) (6,029) (1,231)  
Loss for the period   (91,357) (10,847) (374,511) (188,030) (140,287)
Total comprehensive loss attributable to:            
Equity holders of the parent   (95,110) (12,220) (370,184) (183,220) (149,980)
Non-controlling interest     (381) (6,029) (1,231)  
Total comprehensive loss for the year   $ (95,110) $ (12,601) $ (376,213) $ (184,451) $ (149,980)
Loss per share            
Net loss per share, Basic and Diluted (in usd per share)   $ (0.24) $ (0.04) $ (1.36) $ (0.77) $ (0.58)
Weighted average shares outstanding, Basic and Diluted (in shares)   384,531,450 245,229,566 271,321,253 242,935,770 241,903,166